Other languages Inhibrx, Inc.

Equities

Delayed Nasdaq Other stock markets 03:48:06 2024-06-10 pm EDT			5-day change	1st Jan Change
16.49 ^USD	-0.96%		0.00%	-56.58%

Jun. 04	Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	MT
May. 31	Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	CI

Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	Jun. 04
Inhibrx, Inc. Announces Management Changes	May. 30
Sanofi : a finalisé l'acquisition d'Inhibrx	May. 30
Sanofi Closes Purchase of US Biotech Company Inhibrx	May. 30
Sanofi : finalisation de l'acquisition d'Inhibrx	May. 30
Sanofi boucle le rachat d'Inhibrx dont le montant pourrait atteindre 2,2 mds de dollars	May. 30
Sanofi/Inhibrx : Una situacion especial	May. 30
Inhibrx, Inc. completed the Spin-Off of 92% stake in Inhibrx Biosciences, Inc..	May. 29
Aventis Inc. completed the acquisition of Inhibrx, Inc. from a group of shareholders.	May. 29
Sanofi/Inhibrx : Situation spéciale	May. 29
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Inhibrx Shares Fall After Q4 Net Loss Widens	Feb. 28
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Le bric-à-brac de Zonebourse : Trois records historiques, une galaxie lointaine et du M&A	Feb. 06
Arecor Therapeutics hails Arestat as 2023 performance "strong"	Feb. 01
Arecor pleased as investee Inhibrx sells therapy to Sanofi	Jan. 23
Sector Update: Health Care Stocks Decline Late Afternoon	Jan. 23
Sector Update: Health Care	Jan. 23
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion	Jan. 23

No results for this search